

## WHITEPAPER

# A Comparative Analysis of a Comprehensive Genomic Profiling (CGP) report from a market leading provider with a Genomate Report

Precision oncology is rapidly transforming cancer treatment by tailoring therapeutic strategies to individual patients' genetic profiles. An analysis of 39 reports from a world-leading molecular insights provider (that Genomate reanalyzed) reveals a significant gap in actionable treatment recommendations. Notably, 45% of these reports fail to provide any therapeutic guidance, leaving patients and healthcare providers without clear options.

This white paper compares the results of the gold standard for cancer genomic testing reports with those from Genomate, demonstrating how the Genomate Report can fill the gaps by providing critical therapeutic insights when other lab reports do not.

**Report from leading provider**
**vs.**
**Genomate Report**

55% have treatment options and provide actionable information to the oncologist and patient

100% of the time, the Genomate report provides actionable information to the oncologist and patient\*

45% of patients have no treatment options

19% with GDS 1000

When no information is found in other vendors' reports, Genomate can identify a treatment that will likely improve the patient's outcome. GDS scores over 1000 indicate a high likelihood of benefit from recommended therapies, as they target key tumor drivers with strong evidence, potentially leading to better disease control and longer survival.

26% with GDS 0-1000

When other vendors' reports do not provide information, Genomate can find treatment information that could provide beneficial outcomes 26% of the time.

GDS scores between 0 and 1000 indicate potential moderate effectiveness. They show some positive association with the tumor profile, but the evidence is not as strong.


 26% on-label options  
 29% only off-label options  
 45% no options

 85% on-label options  
 100% off-label options

# Why use Genomate®?

## 1. Enhanced Personalization Through Comprehensive Analysis

The Genomate Report delves deep into the totality of a patient's molecular profile, considering the full spectrum of genetic mutations, biomarkers, and molecular interactions. This comprehensive approach ensures that treatment recommendations are not just based on individual mutations but are genuinely personalized, considering the complex interplay of factors that define each patient's cancer. This level of detail can lead to more precise and effective treatment options.

## 2. Broader Spectrum of Actionable Insights

The Genomate Report consistently delivers a higher rate of actionable treatment recommendations, with 100% of reports offering clear options compared to 55% in other reports. With Genomate, oncologists will receive actionable information to make informed decisions on their patient's care, providing hope even in challenging cases.

## 3. Innovation in Drug Scoring and Treatment Discovery

The Genomate Report employs the sophisticated Genomate Drug Score (GDS) system that assesses the potential efficacy of various therapies based on the patient's unique genetic profile. This innovative scoring system helps identify promising treatment options, even when other reports do not offer clear recommendations. Genomate's ability to discover viable treatment avenues when others provide limited guidance makes it a powerful tool in the fight against cancer.

## 4. A Safety Net for Complex Cases

In oncology, time and options are of the essence. The Genomate Report acts as a safety net, offering alternative treatment strategies when other diagnostic tools may fall short. This capability is particularly crucial for patients with complex or rare cancers, where standard treatment paths may be blurry.

## 5. Flexibility and Complementarity

While the Genomate Report excels as a standalone tool, it also complements other molecular diagnostic tests. This flexibility allows healthcare providers to integrate insights from multiple sources, ensuring that no potential treatment is overlooked and that patients receive the most comprehensive care possible. Choosing the Genomate Report means choosing a more thorough, innovative, and patient-centered approach to cancer treatment.

## Conclusion

While reports from established diagnostic providers are reliable sources of genomic information, they often follow a single biomarker-single drug paradigm, which often provides little or not actionable information or conversely can overwhelm oncologists with too many treatment options, some of which may even conflict with each other. This dearth or flood of information can make it difficult for healthcare providers to confidently determine the best course of action.

The Genomate Report addresses this challenge by ranking treatments based on a comprehensive analysis of the patient's entire molecular profile. This ranking system simplifies interpretation, allowing oncologists to focus on the most promising therapies without being inundated by excessive and sometimes conflicting data. Rather than just listing drugs associated with individual biomarkers, the Genomate Report prioritizes options in a way that makes clinical decision-making clearer and more efficient.

By integrating all relevant information into a single, actionable framework, the Genomate Report enhances and expands upon the insights provided by other diagnostic tools. It provides a holistic view of potential precision oncology treatment avenues, reducing uncertainty for healthcare providers and ensuring that no important therapy is overlooked.

For healthcare providers and patients seeking to make the most informed decisions about cancer treatment, the Genomate Report stands out as an invaluable tool. Not only does it complement other diagnostic reports, but it also excels in simplifying complex data into ranked, actionable, and personalized treatment recommendations. By incorporating Genomate into the treatment decision-making process, healthcare providers can significantly improve patient outcomes, ensuring that the right treatment options are explored clearly, confidently, and efficiently—the first time, every time.

## Disclaimer

\*The findings presented in this white paper are based on an analysis of a sample size of 39 reports. While the data demonstrates that the Genomate Report often provides actionable treatment recommendations where other diagnostic reports may not, these results are specific to the sample analyzed. This does not guarantee that the Genomate Report will provide actionable information in 100% of cases. The performance of the Genomate Report may vary depending on individual patient profiles, the complexity of the case, and the availability of relevant molecular data. The Genomate Report is not medical advice and is not intended to be relied upon as the basis for any prevention, diagnosis, treatment, or other clinical decision-making. Healthcare professionals may consider or disregard the information to choose between treatment options provided by this report. Healthcare professionals are encouraged to independently review the basis for the information contained in this report and must use their own independent judgment in making any clinical decision regarding an individual patient. The drugs indicated in this report may or may not be registered and/or reimbursed in the specific tumor type in the country in which this report is used. The scores indicated in this report do not guarantee efficacy or lack of efficacy of any treatment. Genomate Health Inc. does not take responsibility for the content or accuracy of this report or any referenced pieces of evidence nor for any decision made by any healthcare professional based on the information contained herein. Genomate® is a clinical decision support software, as described in Section 520(o) of the Federal Food, Drug, and Cosmetic Act (FDCA). None of the statements contained herein have been evaluated by the U.S. Food and Drug Administration. Genomate® is not intended to diagnose, treat, cure, prevent, or mitigate any condition and is not a "device" as such term is defined in Section 201(h) of the FDCA.

## Contact Information

To learn how you can work with Genomate to bring true precision oncology to your physicians and patients please contact:

**Genomate Health Inc**  
Cambridge, MA, United States

[sales@genomate.health](mailto:sales@genomate.health)  
[www.genomate.health](http://www.genomate.health)